Security Snapshot

MoonLake Immunotherapeutics - COMMON STOCK (MLTX) Institutional Ownership

CUSIP: 61559X104

13F Institutional Holders and Ownership History from Q1 2022 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

116

Shares (Excl. Options)

60.84MFull value: 60,840,691 · shares · 30 Sep 2026

Price

$11.70

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-912,398
Value change
-$57,885,937
Number of holders
116
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
80,766,491
SEC-reported price per share
$9.75
Insider filing price
$9.75
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • MLTX - MoonLake Immunotherapeutics - COMMON STOCK is tracked under CUSIP 61559X104.
  • 116 institutions reported positions in Q3 2026.
  • 8 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 173 to 116 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $1.43BFull value: $1,426,745,833 · USD · 30 Jun 2026
    to
    $711.83MFull value: $711,834,514 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 116 institutions filings for Q3 2026.

Open SEC evidence

Security key

61559X104

13F reference period

Q3 2026

13F holders

116

13D/G owners

8

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
8
Security
MLTX
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BIOTECHNOLOGY VALUE FUND L P 20% -12% $298,903,985 16,001,284 0% BVF PARTNERS L P/IL 25 Jun 2026
Deep Track Capital, LP 9.7% +55% $162,860,149 +$68,999,103 7,999,025 +74% Deep Track Capital, LP 30 Jun 2026
T. Rowe Price Investment Management, Inc. 5.3% $87,153,505 4,280,624 T. Rowe Price Investment Management, Inc. 30 Jun 2026
Cormorant Asset Management, LP 4.4% -32% $65,262,616 -$25,959,000 3,205,433 -28% Cormorant Asset Management, LP 30 Jun 2026
PRICE T ROWE ASSOCIATES INC /MD/ 4.7% -12% $117,334,991 -$14,571,725 2,974,271 -11% T. Rowe Price Associates, Inc. 31 Mar 2025
Avoro Capital Advisors LLC 3.2% -48% $14,340,000 -$15,415,500 2,000,000 -52% Avoro Capital Advisors LLC 30 Sep 2025
Chen Bihua 3.1% $108,084,177 1,994,173 Chen Bihua 30 Sep 2025
FMR LLC 1.1% -88% $5,212,098 -$35,678,759 726,931 -87% FMR LLC 30 Sep 2025
As of 30 Sep 2026, 116 institutional investors reported holding
60.84MFull value: 60,840,691 · shares · 30 Sep 2026
shares of MoonLake Immunotherapeutics - COMMON STOCK (MLTX). This represents 75% of the company’s total
80.77MFull value: 80,766,491 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
64%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BVF INC/IL 20% 16,001,284 6.2% $187,215,023
Deep Track Capital, LP 10% 8,105,290 1.6% $94,831,893
T. Rowe Price Investment Management, Inc. 6.5% 5,219,847 0.04% $61,073,000
Cormorant Asset Management, LP 3.5% 2,855,433 2.2% $33,408,566
Weiss Asset Management LP 2.9% 2,341,091 0.32% $27,390,765
TWO SIGMA INVESTMENTS, LP 2.4% 1,976,338 0.02% $23,123,155
Qube Research & Technologies Ltd 2.2% 1,796,273 0.02% $21,016,394
RENAISSANCE TECHNOLOGIES LLC 2.1% 1,717,568 0.03% $20,095,546
Trails Edge Capital Partners, LP 2.1% 1,680,000 2.8% $19,656,000
Logos Global Management LP 1.9% 1,500,000 1.1% $17,550,000
Vivo Capital, LLC 1.7% 1,400,000 1.8% $16,380,000
GREAT POINT PARTNERS LLC 1.1% 855,813 2.6% $10,013,012
RICE HALL JAMES & ASSOCIATES, LLC 1% 839,945 0.52% $9,827,357
ALGERT GLOBAL LLC 0.94% 762,031 0.11% $8,915,763
GOLDMAN SACHS GROUP INC 0.88% 708,942 0% $8,294,621
BANK OF AMERICA CORP /DE/ 0.88% 707,846 0% $8,281,798
Trexquant Investment LP 0.79% 637,362 0.05% $7,457,135
Jump Financial, LLC 0.73% 585,703 0.05% $6,852,725
Vestal Point Capital, LP 0.65% 525,000 0.16% $6,142,500
Duquesne Family Office LLC 0.61% 494,000 0.14% $5,780,000
Susquehanna Portfolio Strategies, LLC 0.33% 269,374 0.06% $3,151,676
Burkehill Global Management, LP 0.31% 250,000 0.13% $2,925,000
CONGRESS ASSET MANAGEMENT CO 0.28% 223,883 0.02% $2,619,431
ACUTA CAPITAL PARTNERS, LLC 0.27% 216,568 2% $2,533,846
Polymer Capital Management (HK) LTD 0.24% 190,739 0.21% $2,231,646

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
19
Headline period
Q3 2026
Rows shown
1-19 of 19
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 60,840,691 $711,834,514 -$57,885,937 $11.70 116
2026 Q2 73,249,125 $1,426,745,833 +$204,214,685 $19.47 173
2026 Q1 63,048,824 $1,173,300,860 +$130,740,817 $18.64 147
2025 Q4 56,366,340 $742,950,479 +$285,748,230 $13.18 131
2025 Q3 37,454,837 $268,355,896 -$543,765,841 $7.17 132
2025 Q2 58,588,386 $2,765,378,029 -$36,637,296 $47.20 129
2025 Q1 59,723,013 $2,333,397,891 -$153,122,113 $39.07 134
2024 Q4 63,244,825 $3,424,722,298 +$68,390,992 $54.15 114
2024 Q3 62,105,859 $3,131,140,770 +$81,133,174 $50.42 108
2024 Q2 60,656,094 $2,667,012,692 +$45,095,266 $43.97 109
2024 Q1 59,346,206 $2,980,958,004 +$1,466,170 $50.23 112
2023 Q4 58,433,271 $3,528,831,635 +$147,969,282 $60.39 124
2023 Q3 56,323,727 $3,210,450,399 +$46,563,145 $57.00 118
2023 Q2 56,057,516 $2,858,934,462 +$861,230,424 $51.00 82
2023 Q1 39,419,149 $843,176,754 +$59,244,738 $21.39 43
2022 Q4 37,748,780 $396,358,589 +$8,234,061 $10.50 32
2022 Q3 36,855,847 $291,356,995 +$3,123,162 $7.76 24
2022 Q2 36,470,008 $190,106,000 +$182,848,000 $5.25 22
2022 Q1 653,872 $7,258,000 +$7,258,000 $11.10 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .